Orchard Therapeutics - U.S.’s Post

FDA approves Donanemab for early symptomatic AD. APOE4 testing recommended, not compulsory and patients can be on anticoagulants, if I read correctly. Lots of interesting things here

Groundbreaking Alzheimer's Therapy Targets Amyloid Plaques INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The FDA has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly's revolutionary treatment for early symptomatic Alzheimer's disease. Kisunla is the first amyloid plaque-targeting therapy with evidence supporting therapy cessation once plaques are removed, potentially lowering treatment costs and reducing infusions. This breakthrough offers hope to those with mild cognitive impairment and early-stage dementia. As with all therapies, consult your doctor before starting treatment. #AlzheimersBreakthrough #Kisunl #AmyloidPlaques #DementiaTreatment #CognitiveHealth #Neurology #AlzheimersAwareness #MedicalInnovation

Clinical research and development that is life changing. This approval is amazing and will be life changing for so many. This hits close to home and is personal for me and my family. Wonderful news for society, Lilly - the hard work has now come to fruition. #lifechanging #dementia #alzheimers #personal #clinicalresearch #clinicaldevelopment #neuroscience #hitshome #patientsfirst #caregivers #providers

🚀 Exciting News in Alzheimer's Treatment! 🚀 禮來 Eli Lilly's new drug, Kisunla™, has demonstrated incredible results, slowing cognitive decline by 35% and reducing disease progression risk by 39%. This first-of-its-kind therapy, requiring once-monthly infusions, also achieved an 84% reduction in amyloid plaques. Effective tracking of this medication is crucial to ensure patient safety and inform clinical strategies. To enhance patient monitoring, Instant NanoBiosensors offers a groundbreaking blood detection system that is: 🌍High Accessibility: Designed for portability and ease of use 🌍Low Cost: Detection costs can be reduced by at least 50% 🌍Ultra-Sensitivity: Detection limit in the range of pg/mL to fg/mL We are eager to combine Kisunla’s innovative treatment with Instant NanoBiosensors' advanced monitoring to revolutionize Alzheimer’s care, improving outcomes and providing new hope for patients. 💪 #HealthcareInnovation #AlzheimersTreatment #Biotech #PatientCare #EliLilly #InstantNanoBiosensors

As pharmacists and healthcare professionals, one of the most difficult and stressful experiences we can encounter is making an error. Whether it's a misjudgment in dosage, a miscommunication, or a simple oversight, the consequences can be profound and far-reaching. 💡 Creating a healthy workplace culture isn't something that happens by chance. It requires careful thought about what is going well, what could go wrong, and what the consequences could be. ☘ Join us for this conversation where we will share how you can prevent, manage and respond to, the impact of errors on your mental health and well-being. You can click the link below to register and we hope to see you there! #PharmacyPractice #PatientSafety #HealthcareProfessionals #ContinuousImprovement #ErrorManagement #PatientCare #ProfessionalDevelopment

Virginia patients living with #RareDiseases are counting on the next medical breakthrough to be a life-changer. However, House Bill 570 and Senate Bill 274, which would establish a prescription drug affordability board (#PDAB) in Virginia, will undercut critical investments needed to develop new medications and force patients to lose out on the treatments they’ve spent their lives waiting for.    This #RareDiseaseDay, Gov. Glenn Youngkin and Virginia lawmakers must protect patients living with rare conditions and oppose House Bill 570 and Senate Bill 274. Learn more: https://bit.ly/48lKgxi

For Healthcare Professionals Only: A baby’s skin is around 30% thinner than an adult’s skin and is more prone to losing moisture and drying out, so all products used on a baby’s skin should be as mild and gentle as possible. Take this FREE #CPD module from Health Professional Academy. You can also use this module towards your revalidation with the GPhC. Read more here: https://lnkd.in/gV48qEYQ #Pharmacy #Pharmacist #GPhC #cpd #GPHCC

“The FDA continues to seek new ways to advance science to address the public health challenges that families and communities across the country face,” said FDA Commissioner Robert M. Califf, M.D. “We are committed to helping industry develop solutions that are proven to be effective to address the devastation caused by the overdose crisis. This draft guidance for device studies should prompt industry to collect more comprehensive, timely and diverse data to support device submissions that may help improve the lives of those with opioid use disorder. These and similar efforts will continue to advance within the agency, with the input from industry, stakeholders and, most importantly, those managing opioid use disorder.” In response to the ongoing opioid crisis and its devastating impact on public health, the Food and Drug Administration (FDA) has taken decisive measures to encourage and expedite the development of innovative medical devices designed to treat Opioid Use Disorder (OUD). By fostering an environment of collaboration and expedited regulatory processes, the FDA aims to support the introduction of effective, safe, and accessible solutions that can contribute to combating this pressing public health issue. #iyouhealth #fda #clinicaltrials #clinicalresearch #clinicalstudies #medicaldevices #medicaleducation https://lnkd.in/gaPEY-MV

ADVAnce patient expectations and outcomes with one device. FDA/CE-cleared for 25 indications on virtually all skin types, it is a practitioner and patient favorite! No numbing and no social downtime makes it a treatment plan patients want to stick to… and tell their friends about. 📸: @drfernandomacedo #nofilterjustadva #dyschromia #sundamage #yellowlight #yellowlaserenergy #skintransformation

Science matters...